A robot-aided study in the journal Scientific Reports found that triclosan inhibits not just enoyl reductase but also the enzyme dihydrofolate reductase in malarial parasites. The robot, called Eve, was developed to use artificial intelligence and machine learning to run faster laboratory experiments.
The Zimbabwe Healthcare Fund will receive $502 million over three years from the Global Fund to Fight AIDS, Tuberculosis and Malaria. Most of the funding will go toward providing HIV prevention, care and support.
GC Pharma of South Korea has been granted approval by the country's Ministry of Food and Drug Safety to proceed with a Phase II/III clinical study of its Hepabig-gene recombinant hepatitis B immunoglobulin. The multi-center study will compare Hepabig-gene with current treatments for liver transplant recipients with hepatitis B.
A Series A funding round brought in $58 million for Pandion Therapeutics. The company is developing bispecific antibodies as potential treatments for autoimmune liver diseases and inflammatory bowel disease.
CDC and Brazilian researchers analyzed data on Zika virus infections and microcephaly for births in Brazil's Paraiba state between Aug. 1, 2015, and Feb. 1, 2016, and found that infants with microcephaly were more likely to have had Zika virus infection or been born to a mother who had Zika infection in the first trimester. The findings were published in The Lancet Child & Adolescent Health.
The CDC reported in the American Journal of Public Health that cases of acute hepatitis C virus infection increased 133% between 2004 and 2014. A 93% jump in substance use disorder treatment admissions related to opioid injection was also noted. Injection drug use is considered the primary risk factor for transmission of HCV.
Onconova Therapeutics announced it will expand enrollment and move forward with a planned late-stage study to evaluate its lead candidate rigosertib as a therapy for patients with treatment-resistant myelodysplastic syndromes. The decision was based on an independent data monitoring committee's interim analysis of preliminary data.
US patients with sickle cell disease will now be able to purchase L-glutamine oral powder, or Endari, after Emmaus Life Sciences announced its availability by prescription. The FDA approved Endari in July for pediatric sickle cell disease patients ages 5 and older.
A supplemental new drug application was approved by the FDA to include overall survival data from a late-stage trial on the label of the drug Kyprolis, or carfilzomib. Kyprolis was developed for the treatment of patients with relapsed or refractory multiple myeloma.
A new review program will be launched jointly by the FDA and the Department of Defense to expedite safety and efficacy review of medical products and devices judged to be essential for lifesaving treatments of US military personnel, with high-priority products for review to include cold-stored platelets, cryopreserved platelets and freeze-dried plasma. At least one workshop will be held by the agency and the department this year to inform FDA guidance on determining "unmet medical needs for battlefield settings," according to an initial blueprint for the initiative.
- Page 1